GlassScriptPhysician profile
Robert Scott Yarish
NPI 1063600880
$180,181.45
in general payments reported to CMS, 2019-2025
14 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.76 · 2020: $1,593 · 2021: $127K · 2022: $51K · 2023: $260 · 2024: $149 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $173,637.25 | 2019-2022 | |
| Merz North America, INC. | $5,029.58 | 2020-2022 | |
| Mentor Worldwide LLC | $466.60 | 2021-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Galderma Laboratories, L.P. | $233.53 | 2019-2025 | Dysport |
| Abbvie INC. | $212.47 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Sientra, INC. | $191.95 | 2020-2021 | |
| Acelrx Pharmaceuticals, INC. | $134.72 | 2021-2022 | |
| Boston Scientific Corporation | $123.10 | 2021 | |
| Apyx Medical Corporation | $41.02 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $27.00 | 2025 | Exparel |
| Davol INC. | $25.89 | 2022 | |
| Integra Lifesciences Corporation | $21.64 | 2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Tela Bio, INC. | $20.46 | 2024 | Ovitex 2s |
| Tepha INC | $16.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Yarish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.